First Heterogeneous Ligand- and Salt-Free Larock Indole Synthesis
COMMUNICATIONS
for CI at the “Centre Commun de Spectromꢀtrie de Masse, References
UMR5246 CNRS-Universitꢀ Claude Bernard Lyon 1”.
Melting points were determined in open capillary tubes and
are uncorrected.
[1] R. J. Sundberg, Indoles, Academic Press, London, 1996.
[2] J. A. Joule, in: Science of Synthesis, Vol. 10, (Ed.: E. J.
Thomas), Thieme, Stuttgart, 2001, p 361.
[3] R. J. Sundberg, in: Comprehensive Heterocyclic
Chemistry, Vol. 4, (Eds.: A. R. Katritzky, C. W. Rees),
Pergamon, Oxford, 1984, p 313.
[4] J. Tois, R. Franzꢀn, A. Koskinen, Tetrahedron 2003, 59,
5395.
[5] L. Joucla, L. Djakovitch, Adv. Synth. Catal. 2009, 351,
673.
[6] B. Robinson, The Fischer Indole Synthesis, John Wiley
& Sons, Chichester, 1982.
Typical Procedure for Palladium-Catalysed
Heteroannulation
The aryl iodide (1 mmol), the alkyne (3 mmol), the appro-
priate base (3 mmol), Pd catalyst (2 mol%) and DMF
(4 mL) were introduced into a tube and sealed. The reactor
was placed under stirring in a preheated oil bath at 1208C.
The reaction completion was monitored by GC. After cool-
ing to room temperature, the reaction mixture was filtered
through a celite pad, which was washed with EtOAc
(100 mL). The resulting organic layer was washed with
Na2CO3 (2ꢃ40 mL) then brine (40 mL). The organic layer
was dried over Na2SO4 and the solvent was removed under
reduced pressure. If necessary (for the silylated compounds),
the crude product was fully deprotected according to the
method A or B before being purified by flash chromatogra-
phy over silica.
Method A: To a solution of crude product dissolved into
MeOH (20 mL) was added 2N HCl (4 mL, 8 equiv.). After
completion (monitored by GC), the resulting mixture was
evaporated and the residue was partitioned between AcOEt
and saturated Na2CO3 solution. The phases were separated
and the organic phase was washed with saturated brine,
dried over Na2SO4 and the solvent was removed under re-
duced pressure to afford the corresponding crude fully de-
protected compound.
[7] G. Battistuzzi, S. Cacchi, G. Fabrizi, Eur. J. Org. Chem.
2002, 2671.
[8] S. Chouzier, M. Gruber, L. Djakovitch, J. Mol. Catal.
A: Chem. 2004, 212, 43.
[9] M. Gruber, S. Chouzier, K. Koehler, L. Djakovitch,
Appl. Catal. A: Gen. 2004, 265, 161.
[10] L. Djakovitch, P. Rollet, Adv. Synth. Catal. 2004, 346,
1782.
[11] S. Cacchi, G. Fabrizi, Chem. Rev. 2005, 105, 2873.
[12] L. Djakovitch, V. Dufaud, R. Zaidi, Adv. Synth. Catal.
2006, 348, 715.
[13] L. Djakovitch, P. Rouge, J. Mol. Catal. A: Chem. 2007,
273, 230.
[14] L. Djakovitch, P. Rouge, R. Zaidi, Catal. Commun.
2007, 8, 1561.
[15] G. Cusati, L. Djakovitch, Tetrahedron Lett. 2008, 49,
2499.
Method B: To a solution of crude product, a 1M solution
of TBAF in THF (2 mL, 2 equiv.) was added. The reaction
completion was monitored by GC. After complete desilyla-
tion, the solution was taken up in EtOAc and the organic
layer washed with saturated Na2CO3 solution, brine, dried
over Na2SO4 and the solvent removed under reduced pres-
sure to afford the corresponding crude desilytated product.
[16] L. Djakovitch, P. Rouge, Catal. Today 2009, 140, 90.
[17] R. C. Larock, S. Babu, Tetrahedron Lett. 1987, 28, 5291.
[18] R. C. Larock, S. Babu, Tetrahedron Lett. 1987, 28, 1037.
[19] R. C. Larock, E. K. Yum, J. Am. Chem. Soc. 1991, 113,
6689.
[20] R. C. Larock, E. K. Yum, M. D. Refvik, J. Org. Chem.
1998, 63, 7652.
1
All compounds were fully characterised through H and
13C NMR, IR, melting point, GC-MS. Additionally, HR-MS
were measured for products. Aniline 2,[43] alkynes 7,[44] 12,[45]
indoles 1,[38] 4 and 5,[46,47] 8 and 9,[48,49] 13–15,[50–52] and benzo-
furans 11,[49] 16[53] gave analytical data in accordance with
the literature. Data are available in the supporting informa-
tion.
[21] G. Huang, R. C. Larock, J. Org. Chem. 2003, 68, 7342.
[22] G. Zeni, R. C. Larock, Chem. Rev. 2006, 106, 4644.
[23] C. C. Felder, K. E. Joyce, E. M. Briley, M. Glass, K. P.
Mackie, K. J. Fahey, G. J. Cullinan, D. C. Hunden,
D. W. Johnson, M. O. Chaney, G. A. Koppel, M.
Brownstein, J. Pharmacol. Exp. Ther. 1998, 284, 291.
[24] D. Dauzonne, J. M. Gillardin, F. Lepage, R. Pointet, S.
Risse, G. Lamotte, P. Demerseman, Eur. J. Med. Chem.
1995, 30, 53.
[25] D. J. Sall, D. L. Bailey, J. A. Bastian, J. A. Buben, N. Y.
Chirgadze, A. C. Clemens-Smith, M. L. Denney, M. J.
Fisher, D. D. Giera, D. S. Gifford-Moore, R. W. Harper,
L. M. Johnson, V. J. Klimkowski, T. J. Kohn, H. S. Lin,
J. R. McCowan, A. D. Palkowitz, M. E. Richett, G. F.
Smith, D. W. Snyder, K. Takeuchi, J. E. Toth, M.
Zhang, J. Med. Chem. 2000, 43, 649.
[26] D. Allsop, G. Gibson, I. K. Martin, S. Moore, S. Turn-
bull, L. J. Twyman, Bioorg. Med. Chem. Lett. 2001, 11,
255.
[27] B. Carlsson, B. N. Singh, M. Temciuc, S. Nilsson, Y.-L.
Li, C. Mellin, J. Malm, J. Med. Chem. 2002, 45, 623.
[28] B. L. Flynn, E. Hamel, M. K. Jung, J. Med. Chem. 2002,
45, 2670.
Supporting Information
Complete descriptions of experimental details and product
characterisation are available as Supporting Information.
Acknowledgements
NB thanks the Rꢀgion Rhꢁne-Alpes for grants. The authors
gratefully acknowledge the Rꢀgion Rhꢁne-Alpes, Programme
CIBLE-2007 (Contract number 07 016376 01/02/03) for
funding and EVONIK for a gift of palladium catalyst.
Adv. Synth. Catal. 2009, 351, 2055 – 2062
ꢁ 2009 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2061